Cravath represented Drug Royalty III LP 1 in connection with its $100 million Rule 144A senior secured notes offering. Drug Royalty III LP 1 is a special purpose limited partnership that owns assets related to pharmaceutical products. The transaction closed on December 7, 2018.
The Cravath team included partner Nicholas A. Dorsey, senior attorney Elizabeth Albert and associates Randall F. Limberg and Samuel A. Lifton on securities matters; partner David J. Kappos, practice area attorney Anthony N. Magistrale and associate Joel Feigenbaum on intellectual property matters; and associate Arvind Ravichandran on tax matters. Seann E. Archibald also worked on securities matters.